Once again, another working week will soon draw to a close. Not a moment too soon, yes? After all, it has been busier than might be expected these last few days. In any event, this is, as you know, our signal to daydream about weekend plans. Our agenda is modest, for now. We plan to catch up on reading, see a few friendly faces and manicure the Pharmalot campus. And what about you? How will you mark the end of the summer? Take a last minute jaunt to somewhere fabulous? Visit old friends, or maybe make new ones? Or you could shop for winter clothes. Well, whatever you do, have a grand time, but be safe. See you soon …
An experimental Alzheimer’s treatment being developed by Biogen was granted fast-track designation by the US Food and Drug Administration, the Wall Street Journal reports. The biotech released trial data showing its drug was given to 165 patients and it practically eradicated the amyloid plaques in brains of those given the highest dose, MIT Technology Review notes. Those plaques are widely thought to be what kills nerve cells and causes memory loss.
In response to the EpiPen controversy — the latest flap over escalating drug prices — Hillary Clinton says she would create a panel of federal officials to determine if price increases for certain drugs are justified, STAT reports. And if the panel finds price hikes were not justified, she would push to punish the manufacturer and make the treatment cheaper.
About the Author Reprints
